Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 20Gastrointestinal Stromal Tumors 9Kidney Neoplasms 6Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Kidney Diseases 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urologic Neoplasms 1Prostatic Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Patient Preference 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Renal Cancer 1Adenoma, Islet Cell 1

Interventions

Mitomycin 2valrubicin 1pembrolizumab 1enfortumab vedotin 1dodecyl maltoside 1avelumab 1atezolizumab 1Sunitinib 1Standard of Care 1Radiation Dose Hypofractionation 1Gemcitabine 1Fluorouracil 1Cisplatin 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Urologic Neoplasms × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡